Comparison of peripheral immune response during chemoradiotherapy (CRT) with and without PD-1 blockade in patients with head and neck squamous cell carcinoma (HNSCC)

Deep learning-based PD-L1 tumor cell (TC) scoring improves survival prediction compared to pathologists on durvalumab-treated NSCLC patients

Immune response in patients treated with autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC from the phase I, open label, dose escalation and cohort expansion study

Correlation between response and HLA type in a randomized phase IIb trial of NeuVax + trastuzumab in HER2 low-expressing breast cancer patients to prevent recurrence

Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors

Phase 1/2 study of mogamulizumab (anti-CCR4), to deplete regulatory T-cells, in combination with PD-1 checkpoint inhibitor nivolumab in subjects with locally advanced or metastatic solid tumors

Identification and profiling of neoantigen-specific T cells in NSCL cancer patients treated with atezolizumab

Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma

HLA class I subtypes are associated with immunerelated adverse events in patients with melanoma treated with ipilimumab

Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma

Peripheral immune monitoring identifies biomarkers of response and toxicity after neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanoma

Characterization of changes in tumor immune microenvironment after treatment with neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanoma

Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab

Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of Tcell activation (VISTA) and PD-L1

Durvalumab treatment-induced transcriptional changes in the tumor microenvironment associated with longer survival in patients with late stage Non- Small Cell Lung Cancer (NSCLC)